Biogen Inc. Files 8-K on Financials

TL;DR

Biogen filed an 8-K on Oct 14, 2025, detailing financial results. Check it out.

AI Summary

Biogen Inc. filed an 8-K on October 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. Biogen Inc. is incorporated in Delaware and headquartered at 225 Binney Street, Cambridge, Massachusetts.

Why It Matters

This filing provides investors with updated information on Biogen's financial performance and operational status, which can influence investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any immediately alarming or significant new information.

Key Players & Entities

• BIOGEN INC. (company) — Filer
• 225 BINNEY STREET (location) — Business Address
• CAMBRIDGE (location) — City
• MA (location) — State
• 02142 (location) — ZIP Code
• October 14, 2025 (date) — Date of Report

FAQ

From the Filing

0000875045-25-000040.txt : 20251014 0000875045-25-000040.hdr.sgml : 20251014 20251014161910 ACCESSION NUMBER: 0000875045-25-000040 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20251014 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251014 DATE AS OF CHANGE: 20251014 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 251391990 BUSINESS ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC. DATE OF NAME CHANGE: 20070427 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 8-K 1 biib-20251014.htm 8-K biib-20251014 0000875045 false 0000875045 2025-10-14 2025-10-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2025 Biogen Inc. (Exact name of registrant as specified in its charter) Delaware 0-19311 33-0112644 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 225 Binney Street , Cambridge , Massachusetts 02142 (Address of principal executive offices; Zip Code)      Registrant’s telephone number, including area code: ( 617 ) 679-2000 Not Applicable (Former name or former address, if changed since last report.)      Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0005 par value BIIB The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02     Results of Operations and Financial Condition Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the third quarter of 2025 will include acquired in-process research and development, upfront and milestone expense of approximately $2 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the third quarter 2025 by approximately ($0.01) per share. During the first quarter of 2025 we began presenting acquired in-process research and development, upfront and milestone expense a